Delphi Diagnostics Information, Including Revenue, Investors, Funding, Competitors & Key Metrics

Delphi Diagnostics provide delphi’s sensitivity to endocrine therapy. It is a gene expression interpretive algorithm that measures potential disease progression on endocrine therapy in patients with hormone receptor positive HER2 negative breast cancer.

Company Highlights
Year Founded

2016

icon-altEmployees

9

Location (HQ)

USA

Since Last Funding

6 years

Monthly Website Visitors

327

icon-altTotal Investment Amt

$500K

Last Funding Round

Series Unknown

icon-altYoY Headcount Growth

12.35%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology Research

Medical

Health Care

Health Diagnostics